iBio (IBIO)
(Delayed Data from AMEX)
$2.52 USD
+0.11 (4.56%)
Updated Jun 4, 2024 03:59 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IBIO 2.52 +0.11(4.56%)
Will IBIO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IBIO
New Strong Sell Stocks for October 29th
IBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IBIO
iBio Closes Sale of Manufacturing Facility in Texas
iBio closes sale of manufacturing facility in Texas
iBio, Inc. Updates Corporate Presentation with Future Outlook
Analysts Offer Insights on Healthcare Companies: Ibio (IBIO) and Werewolf Therapeutics (HOWL)
iBIO’s Strategic Advancements and Technological Edge Justify Buy Rating